Alunbrig 90 mg Tablet

Brand Name: Alunbrig

Molecule: Brigatinib

Strength: 90 mg

Quantity: 28 Tablets

Form: Tablet

Packaging Type: Bottle

Manufacturer/Marketed By: Takeda Pharmaceuticals

Country of Origin: USA

Description

Alunbrig 90 mg Tablet contains Brigatinib, a targeted cancer medicine used to treat ALK-positive metastatic non-small cell lung cancer (NSCLC). It helps slow cancer growth and spread under oncologist supervision.

Benefits

Targets ALK gene–driven lung cancer
Helps slow tumor growth and spread
May improve survival and treatment response
Effective in patients resistant to prior ALK therapies
Convenient oral cancer treatment option

Indications and Usage

Alunbrig 90 mg Tablet is indicated for:

ALK-positive metastatic non-small cell lung cancer (NSCLC) in adults
Treatment of patients previously treated with other ALK inhibitors, including crizotinib

Diagnosis and treatment must be supervised by an oncologist with ALK-positive confirmation.

How it Works

Brigatinib selectively inhibits Anaplastic Lymphoma Kinase (ALK) — a mutated protein that drives cancer growth in certain lung cancers. By blocking ALK signaling, it disrupts cancer cell survival, slowing tumor development and metastasis.

Dosage & Administration

Standard dosing often starts at 90 mg once daily, then may increase as directed
Swallow tablet whole with water
Take with or without food at the same time daily
Do not crush, chew, or split the tablet
Never stop or change dose without oncologist approval
Requires routine liver function, lung, blood pressure, and glucose monitoring